Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Completes $7.2B Patheon Acquisition

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today it has completed its $7.2 billion acquisition of contract development and manufacturing organization (CDMO) Patheon.

In May, Thermo Fisher announced it had agreed to buy Durham, North Carolina-based Patheon, which offers drug development and delivery solutions to pharmaceutical and biopharmaceutical firms, for $35 per share in cash. Thermo Fisher said it has now acquired roughly 138.4 million of Patheon's ordinary shares, representing about 95.3 percent of the company's outstanding shares.

"By adding Patheon's highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers," Thermo Fisher President and CEO Marc Casper said in a statement.

Patheon has approximately 9,000 employees, with facilities across North America and Europe. It generated approximately $1.9 billion in revenue in 2016 and will become part of Thermo Fisher's Laboratory Products and Services segment.

Thermo Fisher said that for the remainder of 2017 the transaction is expected to be approximately $.09 accretive to adjusted earnings per share, which includes $.02 in the third quarter. Additional details of the acquisition's 2017 impact will be provided during Thermo Fisher's third quarter earning call scheduled for late October.

Thermo Fisher noted that it continues to expect to realize total synergies of approximately $120 million by year three following the close of the deal, consisting of approximately $90 million of cost synergies and approximately $30 million of adjusted operating income benefit from revenue-related synergies.

During Tuesday morning trading on the New York Stock Exchange, shares of Thermo Fisher were down $.66 at $177.77.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.